Abstract
| Original language | English |
|---|---|
| Journal | Front. Immunol. |
| Volume | 11 |
| DOIs | |
| Publication status | Published - 2020 |
Keywords
- CD4
- CD8
- human leukocyte antigen class I antigens
- prognosis
- programmed death-ligand 1
- thin melanoma
- time
- tumor-infiltrating lymphocytes
Fingerprint Dive into the research topics of 'Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma: Frontiers in Immunology'. Together they form a unique fingerprint.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma : Frontiers in Immunology. / Sabbatino, F.; Scognamiglio, G.; Liguori, L.; Marra, A.; Anniciello, A.M.; Polcaro, G.; Dal Col, J.; Caputo, A.; Peluso, A.L.; Botti, G.; Zeppa, P.; Ferrone, S.; Pepe, S.
In: Front. Immunol., Vol. 11, 2020.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma
T2 - Frontiers in Immunology
AU - Sabbatino, F.
AU - Scognamiglio, G.
AU - Liguori, L.
AU - Marra, A.
AU - Anniciello, A.M.
AU - Polcaro, G.
AU - Dal Col, J.
AU - Caputo, A.
AU - Peluso, A.L.
AU - Botti, G.
AU - Zeppa, P.
AU - Ferrone, S.
AU - Pepe, S.
N1 - Export Date: 5 March 2021 Correspondence Address: Sabbatino, F.; Department of Medicine, Italy; email: fsabbatino@unisa.it Correspondence Address: Sabbatino, F.; Oncology Unit, Italy; email: fsabbatino@unisa.it Funding details: CODICE 2017PHRC8X_003 Funding text 1: The work was supported by Ministero dell’ Università e della Ricerca (Progetti di Rilevante Interesse Nazionale (PRIN), 2017, CODICE 2017PHRC8X_003) (to SP). References: Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D.M., Piñeros, M., Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods (2019) Int J Cancer, 144. , ; Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2019 (2019) CA Cancer J Clin, 69, pp. 7-34. , –, ; Balch, C.M., Gershenwald, J.E., Soong, S.-J., Thompson, J.F., Atkins, M.B., Byrd, D.R., Final version of 2009 AJCC melanoma staging and classification (2009) J Clin Oncol, 27. , ; Durham, A.B., Schwartz, J.L., Lowe, L., Zhao, L., Johnson, A.G., Harms, K.L., The natural history of thin melanoma and the utility of sentinel lymph node biopsy (2017) J Surg Oncol, 116. , ; Yonick, D.V., Ballo, R.M., Kahn, E., Dahiya, M., Yao, K., Godellas, C., Predictors of positive sentinel lymph node in thin melanoma (2011) Am J Surg, 201. , discussion 327–28. ; Maurichi, A., Miceli, R., Camerini, T., Mariani, L., Patuzzo, R., Ruggeri, R., Prediction of survival in patients with thin melanoma: results from a multi-institution study (2014) J Clin Oncol, 32. , ; Brandner, J.M., Haass, N.K., Melanoma’s connections to the tumour microenvironment (2013) Pathology, 45. , ; Fischer, G.M., Vashisht Gopal, Y.N., McQuade, J.L., Peng, W., DeBerardinis, R.J., Davies, M.A., Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications (2018) Pigment Cell Melanoma Res, 31, pp. 11-30. , –, ; Azimi, F., Scolyer, R.A., Rumcheva, P., Moncrieff, M., Murali, R., McCarthy, S.W., Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma (2012) J Clin Oncol, 30. , ; Donizy, P., Kaczorowski, M., Halon, A., Leskiewicz, M., Kozyra, C., Matkowski, R., Paucity of tumor-infiltrating lymphocytes is an unfavorable prognosticator and predicts lymph node metastases in cutaneous melanoma patients (2015) Anticancer Res, 35; Fortes, C., Mastroeni, S., Mannooranparampil, T.J., Passarelli, F., Zappalà, A., Annessi, G., Tumor-infiltrating lymphocytes predict cutaneous melanoma survival (2015) Melanoma Res, 25. , ; Park, C.K., Kim, S.K., Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma (2017) Oncotarget, 8. , ; Saldanha, G., Flatman, K., Teo, K.W., Bamford M. A Novel Numerical Scoring System for Melanoma Tumor-infiltrating Lymphocytes Has Better Prognostic Value Than Standard Scoring (2017) Am J Surg Pathol, 41. , ; Thomas, N.E., Busam, K.J., From, L., Kricker, A., Armstrong, B.K., Anton-Culver, H., Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study (2013) J Clin Oncol, 31. , ; Weiss, S.A., Han, S.W., Lui, K., Tchack, J., Shapiro, R., Berman, R., Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma (2016) Hum Pathol, 57. , ; Eriksson, H., Frohm-Nilsson, M., Järås, J., Kanter-Lewensohn, L., Kjellman, P., Månsson-Brahme, E., Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study (2015) Br J Dermatol, 172. , ; De Panfilis, G., Campanini, N., Santini, M., Mori, G., Tognetti, E., Maestri, R., Phase- and Stage-Related Proportions of T Cells Bearing the Transcription Factor FOXP3 Infiltrate Primary Melanoma (2008) J Invest Dermatol, 128. , ; Erdag, G., Schaefer, J.T., Smolkin, M.E., Deacon, D.H., Shea, S.M., Dengel, L.T., Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma (2012) Cancer Res, 72. , ; Frydenlund, N., Mahalingam, M., PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies (2017) Hum Pathol, 66, pp. 13-33. , –, ; Hicklin, D.J., Wang, Z., Arienti, F., Rivoltini, L., Parmiani, G., Ferrone, S., beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma (1998) J Clin Invest, 101. , ; Kakavand, H., Vilain, R.E., Wilmott, J.S., Burke, H., Yearley, J.H., Thompson, J.F., Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases (2015) Mod Pathol, 28. , ; Obeid, J.M., Erdag, G., Smolkin, M.E., Deacon, D.H., Patterson, J.W., Chen, L., PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome (2016) Oncoimmunology, 5, p. e1235107. , ; Park, S.L., Buzzai, A., Rautela, J., Hor, J.L., Hochheiser, K., Effern, M., Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin (2019) Nature, 565. , ; Requena, C., Botella-Estrada, R., Traves, V., Nagore, E., Almenar, S., Guillén, C., Problems in Defining Melanoma Regression and Prognostic Implication (2009) Actas Dermo-Sifiliográficas (English Edition), 100. , ; Smoller, B.R., Histologic criteria for diagnosing primary cutaneous malignant melanoma (2006) Mod Pathol, 19. , (,):, ; Zurac, S., Negroiu, G., Petrescu, S., Andrei, R., Tebeica, T., Popp, C., Spectrum of morphologic alterations of regression in cutaneous melanoma–potential for improving disease prognosis (2012) Rom J Intern Med, 50; Osella-Abate, S., Conti, L., Annaratone, L., Senetta, R., Bertero, L., Licciardello, M., Phenotypic characterisation of immune cells associated with histological regression in cutaneous melanoma (2019) Pathology, 51. , ; Stam, N.J., Spits, H., Ploegh, H.L., Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products (1986) J Immunol, 137; Sernee, M.F., Ploegh, H.L., Schust, D.J., Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents (1998) Mol Immunol, 35. , ; Perosa, F., Luccarelli, G., Prete, M., Favoino, E., Ferrone, S., Dammacco, F., Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide (2003) J Immunol, 171. , ; Sabbatino, F., Villani, V., Yearley, J.H., Deshpande, V., Cai, L., Konstantinidis, I.T., PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma (2016) Clin Cancer Res, 22. , ; Sabbatino, F., Marra, A., Liguori, L., Scognamiglio, G., Fusciello, C., Botti, G., Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature (2018) J Immunother Cancer, 6, p. 126. , ; Ogino, T., Bandoh, N., Hayashi, T., Miyokawa, N., Harabuchi, Y., Ferrone, S., Association of Tapasin and HLA Class I Antigen Down-Regulation in Primary Maxillary Sinus Squamous Cell Carcinoma Lesions with Reduced Survival of Patients (2003) Clin Cancer Res, 9; Balch, C.M., Wilkerson, J.A., Murad, T.M., Soong, S.J., Ingalls, A.L., Maddox, W.A., The prognostic significance of ulceration of cutaneous melanoma (1980) Cancer, 45. , ; Shen, S., Wolfe, R., McLean, C.A., Haskett, M., Kelly, J.W., Characteristics and associations of high-mitotic-rate melanoma (2014) JAMA Dermatol, 150. , ; Dessinioti, C., Dimou, N., Geller, A.C., Stergiopoulou, A., Lo, S., Keim, U., Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers (2019) J Natl Cancer Inst, 111. , ; Lundgren, S., Fagerström-Vahman, H., Zhang, C., Ben-Dror, L., Mardinoglu, A., Uhlen, M., Discovery of KIRREL as a biomarker for prognostic stratification of patients with thin melanoma (2019) Biomark Res, 7. , ; Chen, Y.-P., Zhang, Y., Lv, J.-W., Li, Y.-Q., Wang, Y.-Q., He, Q.-M., Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications (2017) Theranostics, 7. , ; Marzagalli, M., Ebelt, N.D., Manuel, E.R., Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment (2019) Semin Cancer Biol, 59. , ; Wieder, T., Brenner, E., Braumüller, H., Röcken, M., Immunotherapy of melanoma: efficacy and mode of action (2016) J Dtsch Dermatol Ges, 14, pp. 28-37. , –, ; Eggermont, A.M.M., Blank, C.U., Mandala, M., Long, G.V., Atkinson, V., Dalle, S., Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (2018) N Engl J Med, 378. , ; Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma (2015) N Engl J Med, 373, pp. 23-34. , –, ; Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Nivolumab in previously untreated melanoma without BRAF mutation (2015) N Engl J Med, 372. , ; Robert, C., Thomas, L., Bondarenko, I., O’Day, S., Weber, J., Garbe, C., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma (2011) N Engl J Med, 364. , ; Weber, J., Mandala, M., Del Vecchio, M., Gogas, H.J., Arance, A.M., Cowey, C.L., Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma (2017) N Engl J Med, 377. , ; Clemente, C.G., Mihm, M.C., Bufalino, R., Zurrida, S., Collini, P., Cascinelli, N., Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma (1996) Cancer, 77. , ; van Houdt, I.S., Sluijter, B.J.R., Moesbergen, L.M., Vos, W.M., de Gruijl, T.D., Molenkamp, B.G., Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression (2008) Int J Cancer, 123. , ; Hillen, F., Baeten, C.I.M., van de Winkel, A., Creytens, D., van der Schaft, D.W.J., Winnepenninckx, V., Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma (2008) Cancer Immunol Immunother, 57, pp. 97-106. , –, ; Fu, Q., Chen, N., Ge, C., Li, R., Li, Z., Zeng, B., Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis (2019) Oncoimmunology, 8. , ; Miracco, C., Mourmouras, V., Biagioli, M., Rubegni, P., Mannucci, S., Monciatti, I., Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma (2007) Oncol Rep, 18; Durgeau, A., Virk, Y., Corgnac, S., Mami-Chouaib, F., Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma (2018) Front Immunol, 9. , ; Sade-Feldman, M., Yizhak, K., Bjorgaard, S.L., Ray, J.P., de Boer, C.G., Jenkins, R.W., Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma (2018) Cell, 175, pp. 998-1013.e20. , –, ; Mahmoud, F., Shields, B., Makhoul, I., Avaritt, N., Wong, H.K., Hutchins, L.F., Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack (2017) Cancer Biol Ther, 18. , ; Mascaro, J.M., Castro, J., Castel, T., Lecha, M., Gratacos, R., Mascaro, J.M., Why do melanomas ulcerate (1984) J Cutan Pathol, 11. , ?, :, ; Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma (2010) Cancer, 116. , ; Magnus, K., Prognosis in malignant melanoma of the skin. Significance of stage of disease, anatomical site, sex, age and period of diagnosis (1977) Cancer, 40. , ; Madonna, G., Ballesteros-Merino, C., Feng, Z., Bifulco, C., Capone, M., Giannarelli, D., PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab (2018) Oncoimmunology, 7, p. e1405206. ,
PY - 2020
Y1 - 2020
N2 - Thin melanomas are tumors less than 1 mm thick according to Breslow classification. Their prognosis is in most cases excellent. However, a small subset of these tumors relapses. These clinical findings emphasize the need of novel prognostic biomarkers to identify this subset of tumors. Characterization of tumor immune microenvironment (TIME) is currently investigated as a prognostic and predictive biomarker for cancer immunotherapy in several solid tumors including melanoma. Here, taking into account the limited availability of tumor tissues, by characterizing some of the characteristics of TIME such as number of infiltrating lymphocytes, HLA class I antigen and PD-L1 expression, we show that number of infiltrating CD8+ and FOXP3+ T cells as well as CD8+/FOXP3+ T cell ratio can represent a useful prognostic biomarker in thin melanoma. Although further investigations in a larger patient cohort are needed, these findings have potential clinical significance since they can be used to define subgroups of thin melanoma patients who have a worse prognosis and might need different treatment modalities. © Copyright © 2020 Sabbatino, Scognamiglio, Liguori, Marra, Anniciello, Polcaro, Dal Col, Caputo, Peluso, Botti, Zeppa, Ferrone and Pepe.
AB - Thin melanomas are tumors less than 1 mm thick according to Breslow classification. Their prognosis is in most cases excellent. However, a small subset of these tumors relapses. These clinical findings emphasize the need of novel prognostic biomarkers to identify this subset of tumors. Characterization of tumor immune microenvironment (TIME) is currently investigated as a prognostic and predictive biomarker for cancer immunotherapy in several solid tumors including melanoma. Here, taking into account the limited availability of tumor tissues, by characterizing some of the characteristics of TIME such as number of infiltrating lymphocytes, HLA class I antigen and PD-L1 expression, we show that number of infiltrating CD8+ and FOXP3+ T cells as well as CD8+/FOXP3+ T cell ratio can represent a useful prognostic biomarker in thin melanoma. Although further investigations in a larger patient cohort are needed, these findings have potential clinical significance since they can be used to define subgroups of thin melanoma patients who have a worse prognosis and might need different treatment modalities. © Copyright © 2020 Sabbatino, Scognamiglio, Liguori, Marra, Anniciello, Polcaro, Dal Col, Caputo, Peluso, Botti, Zeppa, Ferrone and Pepe.
KW - CD4
KW - CD8
KW - human leukocyte antigen class I antigens
KW - prognosis
KW - programmed death-ligand 1
KW - thin melanoma
KW - time
KW - tumor-infiltrating lymphocytes
U2 - 10.3389/fimmu.2020.561390
DO - 10.3389/fimmu.2020.561390
M3 - Article
VL - 11
JO - Front. Immunol.
JF - Front. Immunol.
SN - 1664-3224
ER -